Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

$20m for Lutonix's drug-coated balloon tech

This article was originally published in Clinica

  • News

Executive Summary

Minneapolis, Minnesota-based balloon angioplasty specialist Lutonix has raised $20m in series B financing in a round led by Versant Ventures. Previous investors US Venture Partners and RiverVest Venture Partners also contributed to the fundraising. Lutonix said it will use the new capital for product development activities and to initiate human clinical trials of its drug-coated balloon angioplasty catheter. The first targeted indication for the device will be the treatment and prevention of vascular restenosis.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch

CDRH’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

EU Regulatory Roundup, April 2024: EU On Cusp Of Regulatory Shifts Amidst Political Change

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

See All
UsernamePublicRestriction

Register

MT043234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By